Maneesh Dave1, Yujiro Hayashi2, Gabriella B Gajdos2, Thomas C Smyrk3, Phyllis A Svingen1, Sergiy M Kvasha2, Andrea Lorincz2, Haidong Dong4, William A Faubion5, Tamas Ordog6. 1. Gastroenterology Research Unit, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. 2. Gastroenterology Research Unit, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota; Enteric Neuroscience Program, Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota. 3. Department of Pathology, Mayo Clinic, Rochester, Minnesota. 4. Department of Urology, Mayo Clinic, Rochester, Minnesota. 5. Gastroenterology Research Unit, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. Electronic address: faubion.william@mayo.edu. 6. Gastroenterology Research Unit, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota; Enteric Neuroscience Program, Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota; Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota. Electronic address: ordog.tamas@mayo.edu.
Abstract
BACKGROUND & AIMS: After allogeneic transplantation, murine stem cells (SCs) for interstitial cells of Cajal (ICCs), electrical pacemaker, and neuromodulator cells of the gut, were incorporated into gastric ICC networks, indicating in vivo immunosuppression. Immunosuppression is characteristic of bone marrow- and other non-gut-derived mesenchymal stem cells (MSCs), which are emerging as potential therapeutic agents against autoimmune diseases, including inflammatory bowel disease. Therefore, we investigated whether gut-derived ICC-SCs could also mitigate experimental colitis and studied the mechanisms of ICC-SC-mediated immunosuppression in relation to MSC-induced pathways. METHODS: Isolated ICC-SCs were studied by transcriptome profiling, cytokine assays, flow cytometry, mixed lymphocyte reaction, and T-cell proliferation assay. Mice with acute and chronic colitis induced by dextran sulfate sodium and T-cell transfer, respectively, were administered ICC-SCs intraperitoneally and evaluated for disease activity by clinical and pathological assessment and for ICC-SC homing by live imaging. RESULTS: Unlike strain-matched dermal fibroblasts, intraperitoneally administered ICC-SCs preferentially homed to the colon and reduced the severity of both acute and chronic colitis assessed by clinical and blind pathological scoring. ICC-SCs profoundly suppressed T-cell proliferation in vitro. Similar to MSCs, ICC-SCs strongly expressed cyclooxygenase 1/2 and basally secreted prostaglandin E2. Indomethacin, a cyclooxygenase inhibitor, countered the ICC-SC-mediated suppression of T-cell proliferation. In contrast, we found no role for regulatory T-cell-, programmed death receptor-, and transforming growth factor-β-mediated mechanisms reported in MSCs; and transcriptome profiling did not support a relationship between ICC-SCs and MSCs. CONCLUSIONS: Murine ICC-SCs belong to a class different from MSCs and potently mitigate experimental colitis via prostaglandin E2-mediated immunosuppression.
BACKGROUND & AIMS: After allogeneic transplantation, murine stem cells (SCs) for interstitial cells of Cajal (ICCs), electrical pacemaker, and neuromodulator cells of the gut, were incorporated into gastric ICC networks, indicating in vivo immunosuppression. Immunosuppression is characteristic of bone marrow- and other non-gut-derived mesenchymal stem cells (MSCs), which are emerging as potential therapeutic agents against autoimmune diseases, including inflammatory bowel disease. Therefore, we investigated whether gut-derived ICC-SCs could also mitigate experimental colitis and studied the mechanisms of ICC-SC-mediated immunosuppression in relation to MSC-induced pathways. METHODS: Isolated ICC-SCs were studied by transcriptome profiling, cytokine assays, flow cytometry, mixed lymphocyte reaction, and T-cell proliferation assay. Mice with acute and chronic colitis induced by dextran sulfate sodium and T-cell transfer, respectively, were administered ICC-SCs intraperitoneally and evaluated for disease activity by clinical and pathological assessment and for ICC-SC homing by live imaging. RESULTS: Unlike strain-matched dermal fibroblasts, intraperitoneally administered ICC-SCs preferentially homed to the colon and reduced the severity of both acute and chronic colitis assessed by clinical and blind pathological scoring. ICC-SCs profoundly suppressed T-cell proliferation in vitro. Similar to MSCs, ICC-SCs strongly expressed cyclooxygenase 1/2 and basally secreted prostaglandin E2. Indomethacin, a cyclooxygenase inhibitor, countered the ICC-SC-mediated suppression of T-cell proliferation. In contrast, we found no role for regulatory T-cell-, programmed death receptor-, and transforming growth factor-β-mediated mechanisms reported in MSCs; and transcriptome profiling did not support a relationship between ICC-SCs and MSCs. CONCLUSIONS:Murine ICC-SCs belong to a class different from MSCs and potently mitigate experimental colitis via prostaglandin E2-mediated immunosuppression.
Authors: M Dominici; K Le Blanc; I Mueller; I Slaper-Cortenbach; Fc Marini; Ds Krause; Rj Deans; A Keating; Dj Prockop; Em Horwitz Journal: Cytotherapy Date: 2006 Impact factor: 5.414
Authors: Hui Chen; Tamás Ordög; Junwei Chen; David L Young; Michael R Bardsley; Doug Redelman; Sean M Ward; Kenton M Sanders Journal: Physiol Genomics Date: 2007-09-25 Impact factor: 3.107
Authors: Krisztián Németh; Asada Leelahavanichkul; Peter S T Yuen; Balázs Mayer; Alissa Parmelee; Kent Doi; Pamela G Robey; Kantima Leelahavanichkul; Beverly H Koller; Jared M Brown; Xuzhen Hu; Ivett Jelinek; Robert A Star; Eva Mezey Journal: Nat Med Date: 2008-11-21 Impact factor: 53.440
Authors: Manuel A González; Elena Gonzalez-Rey; Laura Rico; Dirk Büscher; Mario Delgado Journal: Gastroenterology Date: 2008-11-27 Impact factor: 22.682
Authors: Andrea Lorincz; Doug Redelman; Viktor J Horváth; Michael R Bardsley; Hui Chen; Tamás Ordög Journal: Gastroenterology Date: 2008-01-18 Impact factor: 22.682
Authors: Viktor József Horváth; Zsuzsanna Putz; Ferenc Izbéki; Anna Erzsébet Körei; László Gerő; Csaba Lengyel; Péter Kempler; Tamás Várkonyi Journal: Curr Diab Rep Date: 2015-11 Impact factor: 4.810
Authors: Yujiro Hayashi; Yoshitaka Toyomasu; Siva Arumugam Saravanaperumal; Michael R Bardsley; John A Smestad; Andrea Lorincz; Seth T Eisenman; Gianluca Cipriani; Molly H Nelson Holte; Fatimah J Al Khazal; Sabriya A Syed; Gabriella B Gajdos; Kyoung Moo Choi; Gary J Stoltz; Katie E Miller; Michael L Kendrick; Brian P Rubin; Simon J Gibbons; Adil E Bharucha; David R Linden; Louis James Maher; Gianrico Farrugia; Tamas Ordog Journal: Gastroenterology Date: 2017-04-21 Impact factor: 22.682
Authors: Maneesh Dave; Kathan Mehta; Jay Luther; Anushka Baruah; Allan B Dietz; William A Faubion Journal: Inflamm Bowel Dis Date: 2015-11 Impact factor: 5.325
Authors: Chih-Min Tang; Tracy E Lee; Sabriya A Syed; Adam M Burgoyne; Stephanie Y Leonard; Fei Gao; Jonathan C Chan; Eileen Shi; Juliann Chmielecki; Deborah Morosini; Kai Wang; Jeffrey S Ross; Michael L Kendrick; Michael R Bardsley; Martina De Siena; Junhao Mao; Olivier Harismendy; Tamas Ordog; Jason K Sicklick Journal: Oncotarget Date: 2016-11-29
Authors: Kevin Lynch; Oliver Treacy; Xizhe Chen; Nick Murphy; Paul Lohan; Md Nahidul Islam; Ellen Donohoe; Matthew D Griffin; Luke Watson; Steven McLoughlin; Grace O'Malley; Aideen E Ryan; Thomas Ritter Journal: Mol Ther Date: 2020-05-30 Impact factor: 11.454